Tislelizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD-1 |
Clinical data | |
Trade names | Tevimbra |
Other names | BGB-A317, tislelizumab-jsgr |
AHFS/Drugs.com | Monograph |
MedlinePlus | a624026 |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous |
Drug class | Antineoplastic agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG |
Tislelizumab, sold under the brand name Tevimbra among others, is a humanized monoclonal antibody directed against programmed death receptor-1.[3] It is being developed by BeiGene.[6]
Tislelizumab was approved for medical use in China in December 2019,[7] in the European Union in September 2023,[4] and in the United States in March 2024.[8]
Medical uses
In China, tislelizumab is indicated to treat people with classical Hodgkin lymphoma who have received at least two prior therapies;[7] and to treat people with locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within twelve months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.[9]
In the EU, tislelizumab is indicated for the treatment of adults with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma after prior platinum-based chemotherapy.[4]
In the US, tislelizumab is indicated for the treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.[3]
Adverse effects
Adverse effects include anemia, leukopenia, thrombocytopenia, nausea, increased aspartate transaminase (AST), neutropenia, fatigue, decreased appetite, vomiting, musculoskeletal pain, constipation, hypoproteinemia and rash.[10] Fatal events such as respiratory infection or failure, and hepatic injury have been reported.[11]
Adverse events are more common when combined with chemotherapy.[12]
Pharmacokinetics
Phase I clinical trial from 2016 has results suggesting an elimination half-life of 11 to 17 days.[13] A 2021 structural and functional analysis suggests a t1/2 of 238 ± 32 minutes, 30- to 80-times higher than pembrolizumab and nivolumab.[14]
History
Phase I trials began in the US and Australia in June 2015.[15] Some early results were announced in July 2016.[16][13]
A phase II clinical trial for urothelial cancer started in China in 2017.[17]
Tislelizumab "demonstrated efficacy and tolerability" in a multicenter phase III trial for advanced hepatocellular carcinoma started in January 2018.[6][18]
Society and culture
Names
Tislelizumab is the international nonproprietary name.[19]
References
- ^ a b "Tevimbra (tislelizumab)". Therapeutic Goods Administration (TGA). 28 June 2024. Retrieved 7 July 2024.
- ^ "Tevimbra (Beigene Aus Pty Ltd)". Therapeutic Goods Administration (TGA). 1 July 2024. Retrieved 7 July 2024.
- ^ a b c "Tevimbra- tislelizumab injection, solution, concentrate". DailyMed. 16 March 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.
- ^ a b c "Tevimbra EPAR". European Medicines Agency. 4 October 2023. Archived from the original on 28 November 2023. Retrieved 5 October 2023.
- ^ "Tevimbra Product information". Union Register of medicinal products. 19 September 2023. Retrieved 1 October 2023.
- ^ a b "BeiGene Initiates Global Phase 3 Trial of Anti-PD-1 Antibody Tislelizumab in Patients with Hepatocellular Carcinoma". BeiGene (Press release). 2 January 2018. Archived from the original on 20 April 2019. Retrieved 20 April 2019 – via GlobeNewswire.
- ^ a b "BeiGene scores first China OK with PD-1 — to be manufactured by Boehringer Ingelheim". Endpoints News. 2 January 2020. Archived from the original on 2 July 2020. Retrieved 1 July 2020.
- ^ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 29 April 2024. Archived from the original on 30 April 2024. Retrieved 30 April 2024.
- ^ "Ploughing through a crowded PD-(L)1 market, BeiGene loads up on promising lung cancer data". Endpoints News. 14 April 2020. Archived from the original on 1 July 2020. Retrieved 1 July 2020.
- ^ Zhou Q, Qin Z, Yan P, Wang Q, Qu J, Chen Y (2023). "Immune-related adverse events with severe pain and ureteral expansion as the main manifestations: a case report of tislelizumab-induced ureteritis/cystitis and review of the literature". Frontiers in Immunology. 14: 1226993. doi:10.3389/fimmu.2023.1226993. PMC 10587548. PMID 37869004.
- ^ Zhang L, Geng Z, Hao B, Geng Q (January 2022). "Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody". Cancer Control. 29: 10732748221111296. doi:10.1177/10732748221111296. PMC 9358212. PMID 35926155.
- ^ Guo Y, Jia J, Hao Z, Yang J (2023). "Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials". Frontiers in Pharmacology. 14: 1172969. doi:10.3389/fphar.2023.1172969. PMC 10318343. PMID 37408759.
- ^ a b Desai J, Markman B, Sandhu SK, Gan HK, Friedlander M, Tran B, et al. (20 May 2016). "A phase I dose-escalation study of BGB-A317, an anti-programmed death-1 (PD-1) mAb in patients with advanced solid tumors". Journal of Clinical Oncology. 34 (15_suppl): 3066. doi:10.1200/JCO.2016.34.15_suppl.3066.
- ^ Hong Y, Feng Y, Sun H, Zhang B, Wu H, Zhu Q, et al. (March 2021). "Tislelizumab uniquely binds to the CC' loop of PD-1 with slow-dissociated rate and complete PD-L1 blockage". FEBS Open Bio. 11 (3): 782–792. doi:10.1002/2211-5463.13102. PMC 7931243. PMID 33527708.
- ^ Clinical trial number NCT02407990 for "Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors" at ClinicalTrials.gov
- ^ Martins I (26 July 2016). "Immunotherapy Trial's Early Results Show Activity in Solid Tumors". Immuno-Oncology News. BioNews Inc. Archived from the original on 2 February 2017. Retrieved 24 January 2017.
- ^ "BeiGene (BGNE) Commences Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer". Archived from the original on 3 July 2020. Retrieved 20 April 2019.
- ^ "Novartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial". Novartis (Press release). Archived from the original on 27 February 2024. Retrieved 2 April 2024.
- ^ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.
External links
- "Tislelizumab-jsgr". National Cancer Institute. 11 April 2024.
- "Tislelizumab (Code C121775)". NCI Thesaurus.
- Clinical trial number NCT03430843 for "A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma" at ClinicalTrials.gov
See what we do next...
OR
By submitting your email or phone number, you're giving mschf permission to send you email and/or recurring marketing texts. Data rates may apply. Text stop to cancel, help for help.
Success: You're subscribed now !